US Moves to Keep Early-Stage Drug Research Domestically as Pharma Shifts Trials Abroad
U.S. officials are taking new steps to encourage pharmaceutical companies to conduct early-stage research and clinical studies domestically, as drugmakers increasingly move trials to China and Australia for faster and cheaper execution.
The U.S. government is introducing measures aimed at retaining early-stage drug research within the country, according to a report. The initiative responds to a growing trend among pharmaceutical firms to relocate clinical trials to China and Australia, where regulatory processes are often quicker and costs lower.
U.S. officials hope that by creating more favorable conditions for domestic trials, they can stem the outflow of innovative research and maintain competitive advantage in drug development. The move underscores ongoing concerns about the erosion of America's leadership in biopharmaceutical innovation.
No specific incentives or funding details have been disclosed yet, but the policy shift signals a strategic priority to anchor early-stage R&D on home soil as global competition for clinical trial activity intensifies.
Source: First Squawk